nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors

Hatem H Soliman
Department of Oncologic Sciences, Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL, USA

Abstract: Tumors recognized by the host immune system are associated with better survival. However, the immune system is often suppressed in patients with established tumor burden. Stimulating the immune system to detect and kill tumor cells has been a challenge in cancer therapy for some time. Recently, novel cancer immunotherapies, such as immune checkpoint inhibitors, monoclonal antibodies, and vaccine therapies, have emerged as promising therapeutic approaches for many solid tumors. However, for some tumors, immunotherapy alone has not provided significant benefits, and some may even be fully resistant to immunotherapy. It has been suggested that the immune system may require “priming” before an immunotherapy can elicit an immune response. Although chemotherapies are believed to be immunosuppressive, when given at the right dose and sequence these agents may provide this “priming” effect for the immune system. In addition to direct cytotoxic killing of tumor cells, standard chemotherapeutic agents can elicit immunogenicity through various mechanisms. This review highlights the general immunomodulatory properties of chemotherapeutic agents. It also provides a rationale for combined therapy with nab-paclitaxel and immune checkpoint inhibitors. Recent clinical trial data with these combination regimens in solid tumors are presented, along with a summary of ongoing trials.

Keywords: immunotherapy, chemotherapy, nab-paclitaxel, checkpoint inhibitors, solid tumors

Introduction
The immune system has the unique ability to specifically detect and rid our body of tumor cells.1,2 Some tumor cells have aberrant expression of surface antigens, including expression of non-self-antigens or altered expression of self-antigens. These abnormalities help the immune system distinguish tumor cells from normal cells.1 Immune recognition and killing of tumor cells is often initiated with the capture of tumor-cell antigens by antigen-presenting cells, including dendritic cells.3 Activated (or antigen-loaded) dendritic cells present tumor-specific antigens to T cells and generate a T-cell response in lymphoid tissues that is specific to the antigen presented. Subsequently, T cells (CD8+ cytotoxic T lymphocytes) infiltrate the tumor microenvironment and kill tumor cells in an antigen-specific manner. Tumor killing promotes more antigen release, and the cycle continues under normal conditions. However, a prolonged presence of cytokines and immune cells within the tumor microenvironment (chronic inflammation) may lead to cytotoxic T-lymphocyte anergy and can promote tumor growth and metastasis.3,4

In patients with cancer, the immune system has failed to recognize tumor cells as abnormal or has lost the ability to kill tumor cells.5 Many mechanisms exist within tumor cells for evading or escaping immune detection, including the ability to downregulate...
antigen expression, which allows tumors to go undetected;\(^3\) to upregulate surface ligands that mediate T-cell exhaustion or inhibit T-cell function (eg, lymphocyte-inhibitory receptors, such as PD1 and CTLA4);\(^5,6\) and to secrete factors that locally block cytotoxicity, suppress T-cell activation, or promote expansion of regulatory T cells, which dampen the immune response.\(^3,4\) For example, overexpression of PDL1 on tumor cells can lead to increased PD1–PDL1 interaction, allowing tumor cells to evade host immune response through T-cell suppression and reduction of cytokine production and T-cell proliferation.\(^7\) Other coinhibitory molecules, including BTLA and VISTA, have also been shown to play suppressive roles in cancer immunity.\(^1\) Recently, studies showed that the CD73–adenosine pathway regulated tumor proliferation, survival, migration, and invasion. Therefore, blockade of CD73 or adenosine could promote antitumor immunity and may enhance the activity of first-generation immune-checkpoint inhibitors.\(^8\)

In addition, tumor burden can simply overwhelm the effector cells of the immune system. Some tumor microenvironments are characterized by the absence of chemokines and infiltrating T cells. These tumors may have dense stroma (eg, pancreatic cancer), which prevents immune effectors from gaining entry to the tumor microenvironment. The presence or absence of immune cells within the tumor microenvironment has prognostic significance. In general, tumor microenvironments that have high immune-cell density (ie, T cells, mature dendritic cells)\(^9,12\) or a CD8\(^+\) T-cell infiltrate\(^13,14\) have a better prognosis than tumors with low immune-cell density\(^9,13\) or an increased presence of regulatory T cells.\(^15–18\) Chemotherapy remains an important part of the treatment regimen for many solid tumors. In addition to cytotoxic effects, immunogenic properties of chemotherapy agents may impact the role of chemotherapy in the treatment of many solid tumors, particularly when combined with immunotherapy agents. This review provides an overview of the immunogenic properties of common chemotherapy agents, and also provides a rationale for combining chemotherapy, particularly nab-paclitaxel-based chemotherapy, with checkpoint inhibitors for the treatment of solid tumors.

**Overview of checkpoint inhibitors in the treatment of solid tumors**

Activating the immune system to elicit antitumor immunity was a challenge in cancer treatment until the recent breakthrough of the checkpoint inhibitors (anti-CTLA4, anti-PD1/PDL1), which have emerged as a promising therapeutic approach in many solid tumors (Table 1). The role of checkpoint inhibitors in tumor immunity has been described in detail elsewhere.\(^6,19\) In brief, CTLA4 is expressed on cytotoxic T cells and is upregulated shortly after T-cell activation. CTLA4 has a high affinity for B7 molecules expressed by dendritic cells. The interaction of B7 molecules with CD28 expressed by T cells is the costimulatory

### Table 1 Checkpoint inhibitors approved for the treatment of solid tumors in the US and Europe

<table>
<thead>
<tr>
<th>Checkpoint inhibitor</th>
<th>Target</th>
<th>Immunoglobulin subtype</th>
<th>Indication</th>
<th>Country</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ipilimumab(^2,25)</td>
<td>CTLA4</td>
<td>IgG(_1)</td>
<td>Unresectable/metastatic melanoma</td>
<td>US, Europe</td>
<td>Bristol-Myers Squibb</td>
</tr>
<tr>
<td>Pembrolizumab(^2,26)</td>
<td>PD1</td>
<td>IgG(_1)</td>
<td>Unresectable/metastatic melanoma</td>
<td>US, Europe</td>
<td>Merck</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>PDL1-positive metastatic NSCLC</td>
<td>US, Europe(^a)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Recurrent/metastatic HNSCC(^e)</td>
<td>US</td>
<td></td>
</tr>
<tr>
<td>Nivolumab(^21,31)</td>
<td>PD1</td>
<td>IgG(_4)</td>
<td>Unresectable/metastatic melanoma</td>
<td>US, Europe(^f)</td>
<td>Bristol-Myers Squibb</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Locally advanced/metastatic NSCLC</td>
<td>US, Europe(^f)</td>
<td></td>
</tr>
<tr>
<td>Atezolizumab(^24)</td>
<td>PDL1</td>
<td>IgG(_1)</td>
<td>Locally advanced/metastatic urothelial carcinoma(^e)</td>
<td>US</td>
<td>Hoffmann-La Roche</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Metastatic NSCLC(^f)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Notes:**
- \(^a\)Approved for patients with high PDL1 expression, no EGFR or ALK mutations, and no prior chemotherapy for metastatic disease. Also approved for patients with PD1-positive tumors who have progressed on or after platinum-containing therapy, and if EGFR- or ALK-mutation-positive, patients must have disease progression on FDA-approved therapy for those mutations before receiving pembrolizumab. \(^b\)Locally advanced or metastatic NSCLC. Patients must have received one or more prior chemotherapy regimens, and if EGFR- or ALK-mutation-positive, patients must have received prior treatment with approved therapy for these mutations before receiving pembrolizumab. \(^c\)Indication granted under accelerated approval, and continued approval may be contingent upon verification of clinical benefit. \(^d\)Patients must have disease progression on or after platinum-containing therapy. \(^e\)Approved as single agent for BRAF\(^V_{600E}\)-wild type and under accelerated approval, which may be contingent upon verification of clinical benefit for BRAF\(^V_{600E}\)-mutation-positive melanoma, and for unresectable or metastatic melanoma in combination with ipilimumab. \(^f\)As monotherapy or in combination with nivolumab. \(^g\)Metastatic NSCLC with progression on or after platinum-containing chemotherapy; patients with EGFR or ALK mutations must have disease progression on FDA-approved therapy for these aberrations prior to receiving nivolumab or atezolizumab. \(^h\)Locally advanced or metastatic NSCLC after prior chemotherapy. \(^i\)Patients must have received prior antiangiogenic therapy. \(^j\)With progression during or after platinum-containing chemotherapy, or progression within 12 months of neoadjuvant/adjuvant treatment with platinum-containing therapy.

**Abbreviations:** FDA, US Food and Drug Administration; HNSCC, head and neck squamous cell carcinoma; NSCLC, non-small-cell lung cancer.
signal for T-cell activation. Therefore, CTLA4 binding of B7 molecules suppresses T-cell activity. CTLA4 antibodies, such as ipilimumab and tremelimumab, block CTLA4 from interacting with B7 molecules and enhance T-cell activation. Similarly, another checkpoint molecule, PD1, is expressed by T cells during long-term antigen exposure and activation. Interaction of PD1 with PDL1, expressed on tumor cells and antigen-presenting cells, dampens the T-cell response by inhibiting T-cell activation and proliferation. Antibodies to PD1 (eg, nivolumab and pembrolizumab) and PDL1 (eg, atezolizumab and durvalumab) prevent the interaction of PD1 with PDL1. Over the span of the last 5 years, several checkpoint inhibitors (eg, ipilimumab, nivolumab, pembrolizumab, atezolizumab, and durvalumab) have gained either an indication or breakthrough-therapy designation in multiple solid tumors (eg, melanoma, lung, renal, head and neck, and bladder) based on positive clinical trial data. In 2011, ipilimumab, a CTLA4-specific monoclonal antibody, was the first checkpoint inhibitor approved in the US and Europe based on a nearly 4-month improvement in survival versus a vaccine therapy in a Phase III trial of patients with metastatic melanoma. A few years later, pembrolizumab and nivolumab became the first PD1 inhibitors approved for advanced melanoma based on positive clinical trial data. A Phase III trial in advanced melanoma subsequently demonstrated that combined therapy with ipilimumab (3 mg/kg) plus nivolumab (1 mg/kg) every 3 weeks (q3w) for four doses followed by nivolumab (3 mg/kg) every 2 weeks (q2w) for cycle 3 and beyond led to longer progression-free survival (PFS) compared with either agent alone (11.5 vs 2.9 months with ipilimumab, hazard ratio [HR] for death or disease progression 0.42; HR 0.001) and 6.9 months with nivolumab (HR 0.74, P=NR vs ipilimumab alone). This combination was recently approved in the US for the first-line treatment of patients with unresectable or metastatic melanoma. In addition to activity in melanoma, PD1 inhibitors have demonstrated activity in a number of other cancers, including lung, ovarian, stomach, and kidney cancers.

In 2015, nivolumab was the first immunotherapy approved for the treatment of patients with metastatic non-small-cell lung cancer (NSCLC) and progression during or after platinum-based chemotherapy, nivolumab was initially approved for patients with squamous histology, but this approval was closely followed by an approval in patients with nonsquamous histology. These approvals were based on the results of two Phase III trials. In these trials, nivolumab (3 mg/kg q2w) versus docetaxel reduced the risk of death by 41% (median overall survival [OS] 9.2 vs 6.0 months, HR 0.59; P<0.001) in previously treated patients with advanced squamous NSCLC and by 27% (12.2 vs 9.4 months, HR 0.73; P=0.002) in previously treated patients with nonsquamous NSCLC. The incidence of grade 3 or 4 treatment-related adverse events was lower with nivolumab versus docetaxel (7% vs 55% in squamous NSCLC, 10% vs 54% in nonsquamous NSCLC). Pembrolizumab gained an indication under accelerated approval in the US for the second-line treatment of patients with NSCLC tumors that express PDL1 based on improved tumor response and durability of response; it is now also approved for the treatment of patients with advanced NSCLC and high PDL1 expression with no EGFR/ALK aberrations who have received no prior chemotherapy, as well as patients with metastatic melanoma and patients with recurrent/metastatic squamous cell carcinoma of the head and neck. Recently, atezolizumab, a PDL1 inhibitor, was approved for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have progressed on platinum-based chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy, as well as patients with metastatic NSCLC after progression during or after platinum-containing chemotherapy. Durvalumab is an investigational PDL1 inhibitor that (although not yet approved) has demonstrated antitumor activity in a number of solid tumors.

Chemotherapy in combination with checkpoint inhibitors

For many tumors, checkpoint blockade alone has not provided significant benefits, and some, such as pancreatic tumors, appear to be fully resistant to checkpoint inhibitors. It has been suggested that the immune system may require “priming” prior to or in conjunction with an immunotherapy agent. Although numerous chemotherapy agents have known immunosuppressive adverse events, some may possess this “priming” effect to the host immune system, helping to elicit an antitumor T-cell response. Cytotoxic killing of tumors provides a natural source of cancer-associated antigens. Therefore, combining chemotherapy with a checkpoint inhibitor could create an immunogenic “feedback loop”, increasing antigen presentation and immune response.

Immunomodulatory properties of standard chemotherapy

Chemotherapy has been a mainstay of cancer treatment and will likely remain as such, even with the discovery of
new targeted therapies and immunotherapies. In addition to direct cytotoxic killing of tumor cells, standard chemotherapeutic agents can elicit immunogenicity through various mechanisms. Immunomodulatory properties of common chemotherapies (eg, cyclophosphamide, antimetabolites, anthracyclines, platinum agents, and taxanes) have been reviewed by Bracci et al. In brief, many cytotoxic agents have been shown to recruit immune cells (ie, dendritic cells, macrophages, and natural killer cells) to the tumor microenvironment, enhance tumor-cell death by converting dying tumor cells into endogenous vaccines, stimulate natural killer-dependent antitumor immunity and T-cell responses, induce phagocytosis of cell debris by dendritic cells and antigen presentation to T cells, sensitize tumor cells to cytotoxic T lymphocytes, and disrupt immune suppressor mechanisms by selectively depleting myeloid-derived suppressor cells and suppressing regulatory T cells. These immunomodulatory properties make chemotherapy agents ideal candidates for combination with immunotherapies.

Although high doses of chemotherapy can be immunosuppressive, chemotherapy agents can enhance the antitumor activity of immunotherapeutics when given at an optimal dose (ie, low dose) and sequence. In a preclinical mouse model of platinum-resistant relapsed ovarian cancer, a dose-dense regimen of low-dose paclitaxel/carboplatin versus the maximum-tolerated-dose regimen was less toxic to the immune system, reduced immunosuppression by components of the tumor microenvironment, and stimulated recruitment of macrophages and CD8+ T cells to tumors. Preclinical evidence also supports giving chemotherapy prior to vaccine immunotherapy and at doses slightly higher than the dose levels that begin to induce cytopenias. In a clinical study of patients with metastatic breast cancer, low doses of cyclophosphamide/doxorubicin enhanced the immune response to an allogeneic, HER2-positive, GMCSF-secreting breast-tumor vaccine in patients with breast cancer. In the same study, higher doses of cyclophosphamide were shown to suppress immunity. Therefore, when given at an optimal dose and sequence, chemotherapy may enhance the immune response rather than suppress it. Striking the right balance will be critical to the further development of effective chemotherapy–immunotherapy combination regimens.

**Immunomodulatory properties of taxanes**

Taxanes are widely used chemotherapy agents in the treatment of solid tumors, including breast, lung, and pancreatic cancers, among others. It is well known that taxanes inhibit cell division by stabilizing microtubules, but they can also act as lipopolysaccharide mimetics and can activate macrophages to mediate direct cytotoxicity against tumor cells. Taxanes may also provide long-term immune benefits, have shown to increase tumor-infiltrating lymphocytes, and have demonstrated a positive effect on T-cell proliferation and natural killer-mediated tumor-cell lysis in breast cancer tumors. A greater influx of tumor-infiltrating lymphocytes in breast cancer tumors has been correlated with a better response to chemotherapy. Paclitaxel may be a particularly strong immunostimulant, as it is able to both activate CD8+ T cells and reduce immunosuppressive cells, such as regulatory T cells. Docetaxel has been shown to increase CD8+ T-cell production of IFNγ (a stimulator of tumor-cell killing), but docetaxel does not appear to inhibit the suppressor function of regulatory T cells. In a preclinical model, lower-dose taxanes appeared to induce maturation of myeloid-derived suppressor cells into more mature dendritic cells independently of TLR4. In patients with advanced breast cancer, treatment with paclitaxel or docetaxel was also associated with enhanced natural killer-cell activity. In addition, a study showed that the antitumor effects of paclitaxel may be mediated by myeloid-derived suppressor cells. Taxanes regulate many aspects of immune function, including lymphocyte recruitment and activation and production of immunoenhancing cytokines, including IL-12, IFNγ, TNFα, and GMCSF, all of which may augment the antitumor activity of immunotherapeutics. Tumor cell-derived TGFβ has been shown to inhibit paclitaxel-induced macrophage activation; therefore, depletion of TGFβ may provide a mechanism for restoring the immunomodulatory properties of taxanes.

**Taxane-based chemotherapy with immune-checkpoint inhibitors**

The combination of taxanes with checkpoint inhibitors in solid tumors has been supported in early clinical studies (Table 2). However, to date, no clinical trial has reported results for combined therapy with docetaxel plus a checkpoint inhibitor. In a Phase II trial of paclitaxel/carboplatin and ipilimumab (10 mg/kg) in advanced lung cancer, 204 chemotherapy-naïve patients with NSCLC received (1:1:1) concurrent ipilimumab (four doses of ipilimumab plus paclitaxel/carboplatin followed by two doses of placebo plus paclitaxel/carboplatin), phased ipilimumab (two doses of placebo plus paclitaxel/carboplatin followed by four doses of ipilimumab plus paclitaxel/carboplatin), or a control regimen (up to six doses of placebo plus paclitaxel/carboplatin).
Table 2 Conventional paclitaxel in combination with checkpoint inhibitors

<table>
<thead>
<tr>
<th>Study</th>
<th>n</th>
<th>Population</th>
<th>Treatment</th>
<th>Efficacy</th>
<th>Grade 3/4 AEs</th>
</tr>
</thead>
</table>
| Lynch et al19 | 204 | First-line, stage IIIb/IV or recurrent NSCLC | A Placebo + Pac 175 mg/m² + Carbo AUC 6 q3w =6 doses  
B Concurrent (ipi 10 mg/kg + Pac/Carbo q3w 4 doses → placebo + Pac/Carbo q3w 2 doses)  
C Phased (placebo + Pac/Carbo q3w 2 doses → ipl 10 mg/kg + Pac/Carbo q3w 4 doses) | Best ORR by irRC  
A 18%  
B 21%  
C 32%  
Modified WHO  
A 4.2  
B 4.1  
C 5.1 | (Immune-related) |
| Reck et al21 | 130 | First-line, extensive-disease SCLC | A Placebo + Pac 175 mg/m² + Carbo AUC 6 q3w =6 doses  
B Concurrent (ipi 10 mg/kg + Pac/Carbo q3w 4 doses → placebo + Pac/Carbo q3w 2 doses)  
C Phased (placebo + Pac/Carbo q3w 2 doses → ipl 10 mg/kg + Pac/Carbo q3w 4 doses) | Best ORR by irRC  
A 53%  
B 49%  
C 71%  
Modified WHO  
A 5.2  
B 3.9  
C 5.2 | (Immune-related) |
| Weber et al22 | 59  | First-line, advanced melanoma | A Ipi 10 mg/kg q3w ≤4 doses  
B Ipi ≤4 doses + Dac 850 mg/m² q3w  
C Ipi ≤4 doses + Pac 175 mg/m² + Carbo AUC 6 | Immune-related NR  
A 33%  
B 33%  
C 28%  
Modified WHO  
A 29%  
B 28%  
C 11% | (Treatment-related) |
| Antonia et al23 | 56  | First-line, advanced NSCLC | A Nivo 10 mg/kg q3w + Gem 1,250 mg/m² + Cis 75 mg/m² (squamous, n=12)  
B Nivo 10 mg/kg + Pem 500 mg/m² + Cis 75 mg/m² (non-squamous, n=15)  
C Nivo 10 mg/kg + Pac 200 mg/m² + Carbo AUC 6 q3w (squamous and non-squamous, n=15)  
D Nivo 5 mg/kg + Pac 200 mg/m² + Carbo AUC 6 q3w (squamous and non-squamous, n=14) | RECIST  
A 5.7  
B 6.8  
C 4.8  
D 7.1  
Not reached | Pneumonitis (n=4), fatigue, and acute renal failure (grade 3 only, n=3 each) |
| Jamal et al24 | 30  | Unresectable, advanced melanoma | A Ipi 3 mg/kg q3w 4 doses starting at week 4 (concurrent) + Pac 175 mg/m² + Carbo AUC 6 q3w 5 doses  
B Ipi 3 mg/kg q3w 4 doses (1-week delay) + Pac 175 mg/m² + Carbo AUC 6 q3w 5 doses | 26.7 (by irRC) for all patients NR  
15.9 for all patients | Total ≤7% (Treatment-related) |
| Horinouchi et al25 | 15  | First-line, stage IIIb/IV or recurrent NSCLC (Japanese) | A Phased Ipi 3 mg/kg + Pac 175 mg/m² + Carbo AUC 6 q3w  
B Phased Ipi 10 mg/kg + Pac 175 mg/m² + Carbo AUC 6 q3w | RECIST  
A 3/6  
B 3/7 | Neutropenia (100% vs 100%), leukopenia (50% vs 17%), anemia (0% vs 66.7%) |

(Continued)
Table 2 (Continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>n</th>
<th>Population</th>
<th>Treatment</th>
<th>Efficacy</th>
<th>Grade 3/4 AEs</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>A Pembro 2 or 10 mg/kg + Carbo AUC 6 + Pac 200 mg/m² q3w ×4 → Pem maintenance (any histology, n=25)</td>
<td>A 52%=10 vs NR vs 10</td>
<td>(Treatment-related)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>B Pembro 2 or 10 mg/kg + Carbo AUC 6 + Pac 200 mg/m² q3w + Bev 15 mg/kg ×4 → Pem + Bev maintenance (nonsquamous, n=25)</td>
<td>B 48%=10</td>
<td>A 36%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>C Pembro 2 or 10 mg/kg + Carbo AUC 5 + Pem 500 mg/m² q3w ×4 → Pem + Pem maintenance (nonsquamous, n=24)</td>
<td>C 71%=10</td>
<td>B 46%</td>
</tr>
</tbody>
</table>

Notes: 1Data based on a follow-up OS analysis; 2without EGFR-sensitizing mutation or ALK translocation only; 3confirmed.
Abbreviations: AEs, adverse events; AUC, area under the curve; Bev, bevacizumab; Carbo, carboplatin; Cis, cisplatin; Dac, dacarbazine; Gem, gemcitabine; Ipi, ipilimumab; irRC, immune-related response criteria; Nivo, nivolumab; NR, not reported; NSCLC, non-small-cell lung cancer; Pac, paclitaxel; Pem, pemetrexed; Pembro, pembrolizumab; PFS, progression-free survival; q3w, every 3 weeks; RECIST, Response Evaluation Criteria In Solid Tumors; ORR, overall response rate; OS, overall survival; WHO, World Health Organization.

The phased ipilimumab regimen led to improved median PFS by immune-related response criteria (irRC; primary end point) versus the control paclitaxel/carboplatin regimen (5.7 vs 4.6 months, HR 0.72; P=0.05). The median OS of the phased ipilimumab regimen was nearly 4 months longer compared with the control paclitaxel/carboplatin regimen, but the difference was not significant (12.2 vs 8.3 months, HR 0.87; P=0.23). Median PFS and OS were 5.5 and 9.7 months, respectively, for the concurrent ipilimumab regimen, but were also not significantly different from those for the control paclitaxel/carboplatin regimen. In a subset analysis, patients with squamous NSCLC derived a greater benefit from phased ipilimumab than did patients with nonsquamous NSCLC. The incidence of treatment-related grade 3 or 4 adverse events was similar across the three regimens (37% for the control paclitaxel/carboplatin arm, 39% for phased ipilimumab, and 41% for concurrent ipilimumab), with a greater incidence of immune-related grade 3 or 4 adverse events in the ipilimumab arms (6% for paclitaxel/carboplatin, 15% for phased ipilimumab, and 20% for concurrent ipilimumab). Importantly, the incidence of adverse events typically associated with paclitaxel/carboplatin (fatigue, neuropathy, and neutropenia) was not increased with the addition of ipilimumab.

In a Phase I dose-escalation study in Japanese patients with advanced NSCLC, phased ipilimumab (3 or 10 mg/kg q3w) in combination with paclitaxel/carboplatin also demonstrated antitumor activity and a consistent safety profile. Additionally, a Phase II trial using the phased and concurrent doses/schedules of ipilimumab (10 mg/kg q3w) plus paclitaxel/carboplatin was conducted in chemotherapy-naïve patients with extensive-disease SCLC. Again, phased ipilimumab, but not concurrent ipilimumab, improved median PFS (by irRC) compared with the control paclitaxel/carboplatin regimen (6.4 vs 5.3 months, HR 0.64; P=0.03). Median OS was 10.5, 12.5, and 9.1 months for the control paclitaxel/carboplatin, phased ipilimumab, and concurrent ipilimumab regimens, respectively. Safety results were similar to those noted for the NSCLC trial previously described here.

Taken together, these trials indicate that giving chemotherapy before immunotherapy leads to better outcomes, which may be explained by the “priming effect” that chemotherapy has on the immune system. Another study demonstrated that ipilimumab could be safely combined with dacarbazine or paclitaxel/carboplatin in patients with previously untreated advanced melanoma, but the initial efficacy results of this Phase I trial indicated that the combination of ipilimumab (10 mg/kg q3w) plus paclitaxel/carboplatin did not lead to better outcomes compared with ipilimumab alone or ipilimumab plus dacarbazine. In a Phase II study evaluating concurrent or sequential ipilimumab (3 mg/kg q3w) in combination with paclitaxel/carboplatin in patients with advanced melanoma, no differences in outcomes were observed between the regimens, with a best overall response rate (ORR) of 26.7%, a disease-control rate of 56.7% (by irRC), and a median OS of 15.9 months in all patients. Grade 3/4 adverse events were observed in 63% of patients.
With regard to the PD1/PDL1 inhibitors, early results of two NSCLC trials demonstrated antitumor activity of a PD1 inhibitor combined with paclitaxel-based therapy (Table 2). In a Phase I trial, patients with chemotherapy-naïve NSCLC were assigned to one of four treatment cohorts according to histology: nivolumab (10 mg/kg q3w) plus gemcitabine/cisplatin (squamous, n=12), nivolumab (10 mg/kg q3w) plus paclitaxel/cisplatin (non-squamous, n=15), nivolumab (10 mg/kg q3w) plus paclitaxel/cisplatin (any histology, n=15), or nivolumab (5 mg/kg q3w) plus paclitaxel/cisplatin (any histology, n=14). In 56 evaluable patients, ORRs by Response Evaluation Criteria in Solid Tumors were 33%, 47%, 47%, and 43%, and median OS was 11.6, 19.2, and 14.9 months, and not reached, respectively. The overall incidence of select grade 3 or 4 adverse events was ≤7%. In the Phase I/II KEYNOTE-021 trial, the combination of pembrolizumab (2 or 10 mg/kg q3w) plus paclitaxel/cisplatin for four cycles followed by pembrolizumab maintenance demonstrated an ORR of 52% in chemotherapy-naïve patients with advanced NSCLC. The incidence of grade 3 or 4 adverse events was 36% with this combination regimen.

Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is a form of paclitaxel that, unlike conventional paclitaxel, is formulated without the use of a solvent and does not require steroid premedication to prevent hypersensitivity reactions. In pharmacokinetic and preclinical studies, nab-paclitaxel displayed properties related to its distinct formulation compared with standard paclitaxel, which is formulated with Kolliphor EL (formerly known as Cremophor EL). In these studies, nab-paclitaxel demonstrated tenfold higher mean maximum concentration of free paclitaxel in the plasma of patients with advanced solid tumors, delivery of 33% higher drug concentration to tumors in preclinical xenograft models, enhanced transport across endothelial cell monolayers, and faster and greater tissue penetration and slower elimination of paclitaxel in patients’ tissues, including tumors. Currently, nab-paclitaxel is indicated for the treatment of metastatic breast cancer, advanced NSCLC (in combination with carboplatin), and metastatic pancreatic cancer (in combination with gemcitabine), based on achieving statistical significance for the primary end point in Phase III trials versus a standard-chemotherapy regimen.

Current reports of nab-paclitaxel with checkpoint inhibitors are limited, but early data suggest that nab-paclitaxel-based therapy may augment the antitumor activity of these agents. In a preliminary analysis of a Phase IB trial of patients with various solid tumors, a cohort of 16 efficacy-evaluable patients with advanced NSCLC treated with the combination of atezolizumab (15 mg/kg q3w) plus nab-paclitaxel (100 mg/m² weekly) plus carboplatin achieved an ORR of 56% and a complete response rate of 25%. Two other trial arms of atezolizumab plus either paclitaxel/carboplatin (efficacy evaluable, n=8) or pemetrexed/carboplatin (efficacy evaluable, n=17) also demonstrated favorable ORRs of 50% and 76%, respectively, but no patients receiving the paclitaxel- or pemetrexed-containing regimens have achieved a complete response to date. The most common grade 3 or 4 adverse event was neutropenia (35% in the nab-paclitaxel arm, 29% in the paclitaxel arm, and 25% in the pemetrexed arm). Initial analysis of a cohort of patients with triple-negative breast cancer treated with atezolizumab (800 mg q2w) plus nab-paclitaxel (125 mg/m² weekly for first 3 of 4 weeks) within the same Phase IB trial demonstrated a best ORR of 71% (42% confirmed) in 24 patients evaluable for efficacy. Patients with metastatic triple-negative breast cancer who received the atezolizumab plus nab-paclitaxel regimen as first-line therapy derived the greatest benefit (best ORR, 46% confirmed). A total of 32 patients with triple-negative breast cancer were evaluable for safety. Neutropenia and decreased neutrophil count were the most common grade 3/4 AE, occurring in 47% of patients receiving atezolizumab plus nab-paclitaxel. The investigators also found that expression of PDL1 was mostly restricted to immune cells in excised tumors, but the level of expression did not appear to correlate with response. Based on the positive results of this Phase IB trial, the combination of atezolizumab and nab-paclitaxel is being evaluated in Phase III trials in triple-negative breast cancer and NSCLC (Figure 1).

Early clinical trials have indicated that pancreatic tumors may be fully resistant to monotherapy with immune-checkpoint inhibitors. However, recent data from a mouse-model study demonstrated that this resistance could be overcome with a combination therapy that contained nab-paclitaxel. Treatment with a combination of a CD40 antibody, nab-paclitaxel, gemcitabine, a PD1 antibody, and a CTLA4 antibody led to complete tumor rejection and long-term tumor-free survival in treated mice. nab-Paclitaxel is currently being studied in combination with nivolumab or pembrolizumab in pancreatic cancer (Table 3), as well as with other checkpoint inhibitors (atezolizumab, durvalumab, and ipilimumab) in multiple trials of solid tumors.

**Conclusion**

Tumor-mediated immune suppression and aberrant tumor microenvironments that promote tumor growth and
metastasis are just two of the many challenges to achieving an optimal and sustained treatment response in patients with cancer, especially those with metastatic disease. Chemotherapy agents in general owe part of their antitumor activity to positive changes in the host immune system, such as providing a natural vaccine, recruiting immune cells to the tumor microenvironment, and suppressing regulatory T cells. However, as monotherapy, the ability of chemotherapy to restore antitumor immunity completely is limited. Likewise, immunotherapy agents alone are not always able to fully elicit an attack on tumor cells. Therefore, combinations of chemotherapy and immunotherapy may have mutual benefits. Understanding how a particular chemotherapy agent modulates the immune system will be important to help decide the best immunotherapy–chemotherapy combinations and to maximize therapeutic benefit. However, such a vast array of potential combinations of chemotherapy and immunotherapy agents calls for a cooperative effort to evaluate the various combinations systematically. This is especially true with the limitations in existing preclinical...
models in recapitulating all the complex interactions between the immune system and tumors in a human host. To this end, the Cancer MoonShot 2020 Quantitative Integrative Lifelong Trial program is an ongoing effort to bring together all involved parties to assess various combinations of immunotherapy and chemotherapy agents in a collaborative manner. Indeed, studies are ongoing to determine optimal combinations and schedules of chemotherapy and emerging immunotherapy agents.

Trials are ongoing to determine whether nab-paclitaxel would be an ideal chemotherapy candidate for various immunotherapy combination approaches in solid tumors. nab-Paclitaxel does not appear to have overlapping toxicities with checkpoint inhibitors or to worsen immune-related toxicities. Correlative studies looking at the effects of pharmacokinetics, dosing schedules, drug formulations, and concomitant supportive medications will be important in identifying the ideal immunotherapy combination strategy for nab-paclitaxel. Clinical study results of nab-paclitaxel in combination with checkpoint inhibitors are eagerly awaited.

**Table 3 Clinical development of checkpoint inhibitors + nab-paclitaxel-based chemotherapy in solid tumors**

<table>
<thead>
<tr>
<th>Checkpoint inhibitor</th>
<th>Disease/setting</th>
<th>Phase</th>
<th>ClinicalTrials.gov identifier</th>
</tr>
</thead>
<tbody>
<tr>
<td>PD-1</td>
<td>Nivolumab</td>
<td>NSCLC</td>
<td>I</td>
</tr>
<tr>
<td></td>
<td>MBC</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Metastatic PC</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Advanced NSCLC</td>
<td>I/I</td>
<td>NCT02574078</td>
</tr>
<tr>
<td>Pembrolizumab</td>
<td>Neoadjuvant TNBC</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Advanced NSCLC</td>
<td>I</td>
<td>NCT02622074</td>
</tr>
<tr>
<td></td>
<td>Advanced NSCLC</td>
<td>I/I</td>
<td>NCT021840579</td>
</tr>
<tr>
<td></td>
<td>Metastatic solid tumors</td>
<td>I/I</td>
<td>NCT02331251</td>
</tr>
<tr>
<td></td>
<td>Advanced NSCLC</td>
<td>I</td>
<td>NCT02684461</td>
</tr>
<tr>
<td></td>
<td>HER2 MBC</td>
<td>II</td>
<td>NCT02752685</td>
</tr>
<tr>
<td></td>
<td>Locally recurrent or metastatic TNBC</td>
<td>III</td>
<td>NCT0819518</td>
</tr>
<tr>
<td></td>
<td>Metastatic squamous NSCLC</td>
<td>III</td>
<td>NCT02775435</td>
</tr>
<tr>
<td>PDL-1</td>
<td>Atezolizumab</td>
<td>Solid tumors including metastatic PC</td>
<td>I</td>
</tr>
<tr>
<td></td>
<td>Neoadjuvant NSCLC</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Metastatic non-squamous NSCLC</td>
<td>III</td>
<td>NCT02367781</td>
</tr>
<tr>
<td></td>
<td>Metastatic squamous NSCLC</td>
<td>III</td>
<td>NCT02367794</td>
</tr>
<tr>
<td></td>
<td>Neoadjuvant TNBC</td>
<td>II</td>
<td>NCT02530498</td>
</tr>
<tr>
<td></td>
<td>Metastatic TNBC</td>
<td>II</td>
<td>NCT02425891</td>
</tr>
<tr>
<td></td>
<td>Neoadjuvant TNBC</td>
<td>I/I</td>
<td>NCT02489448</td>
</tr>
<tr>
<td></td>
<td>Metastatic melanoma</td>
<td>I</td>
<td>NCT02685059</td>
</tr>
<tr>
<td></td>
<td>Advanced solid tumors</td>
<td>II</td>
<td>NCT02658214</td>
</tr>
<tr>
<td>CTLA4</td>
<td>Ipilimumab</td>
<td>Metastatic melanoma</td>
<td>II</td>
</tr>
</tbody>
</table>

**Abbreviations:** MBC, metastatic breast cancer; NSCLC, non-small-cell lung cancer; PC, pancreatic cancer; TNBC, triple-negative breast cancer.

**Disclosure**

HHS has served as a scientific advisor and principal investigator for Celgene. The author reports no other conflicts of interest in this work.

**References**


